The Insulin Pump Market - France

The insulin pump market is growing rapidly, driven by the explosion in diabetes prevalence worldwide(537 million people in 2021, compared with 151 million in 2000) and major technological advances in treatment. Estimated at $5.67 billion in 2022, it should reach $9.4 billion by 2028, representing a CAGR of 8.8%. This dynamism is based on growing public health needs, particularly among insulin-dependent diabetics, whose treatment requires precision, regularity and comfort on a daily basis. Insulin pumps are a high-tech alternative to daily multi-injections, and their ability to mimic the natural functioning of the pancreas thanks to a programmable flow rate is particularly appealing. Although only 2% to 5% of diabetic patients are equipped with them today (compared with 25% in the United States), usage is exploding(+256% between 2015 and 2019) and innovation is accelerating: closed-loop systems (artificial pancreas), tubeless "patch" pumps, connected objects, remote medical monitoring. The majority of users are type 1 diabetics (76%), but use is also growing among type 2 patients, notably in the event of injection failure or for improved quality of life. Target groups also include pregnant women and children, as well as patients in situations of medical or social vulnerability. by a worrying rise in obesity(17% in 2020, compared with 8.5% in 1997) and a high prevalence of diabetes in the over-65s (63.6%). The market is structured aroundmajor players such as Medtronic, Roche, Insulet, Diabeloop and Ypsomed, and benefits from a favorable economic model, thanks to 100% reimbursement by the French social security system. The purchase cost of a pump is capped at €2,600 inc. tax, or €3.50 inc. tax/day for rental, with reimbursable consumables.

Within a clear, regulated framework (initial prescription in a center, annual reassessment, compulsory training), this largely under-exploited market represents a major growth opportunity for the Group.represents a major growth opportunity for manufacturers, healthcare service providers and homecare operators, in the service of more effective, personalized diabetes management.